Expanding the reach of highly potent cancer therapies with pre|CISION®
We believe in hope without compromise
The pre|CISION® peptide drug conjugate platform. >
Avacta is seeking to expand its partnerships for targeted cancer therapies. >
We’re delighted to be shortlisted as a finalist at the 2024 Scrip Awards in the ‘Best Oncology R&D Advance’ category >
Latest news